Next Article in Journal
Structural Examination of 6-Methylsulphonylphenanthro- [9,10-C]-furan-1(3H)-one—A Rofecoxib Degradation Product
Next Article in Special Issue
Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases
Previous Article in Journal
Oromucosal Administration of Interferon to Humans
Previous Article in Special Issue
Oxidative Stress Induced Mitochondrial Failure and Vascular Hypoperfusion as a Key Initiator for the Development of Alzheimer Disease
Pharmaceuticals 2010, 3(2), 345-368; doi:10.3390/ph3020345
Review

Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound

,
,
 and *
Received: 23 December 2009; in revised form: 20 January 2010 / Accepted: 25 January 2010 / Published: 28 January 2010
(This article belongs to the Special Issue Mitochondrial Drugs for Neurodegenerative Diseases)
View Full-Text   |   Download PDF [413 KB, uploaded 28 January 2010]   |   Browse Figures
Abstract: Olesoxime (TRO19622) is a novel mitochondrial-targeted neuroprotective compound undergoing a pivotal clinical efficacy study in Amyotrophic Lateral Sclerosis (ALS) and also in development for Spinal Muscular Atrophy (SMA). It belongs to a new family of cholesterol-oximes identified for its survival-promoting activity on purified motor neurons deprived of neurotrophic factors. Olesoxime targets proteins of the outer mitochondrial membrane, concentrates at the mitochondria and prevents permeability transition pore opening mediated by, among other things, oxidative stress. Olesoxime has been shown to exert a potent neuroprotective effect in various in vitro and in vivo models. In particular olesoxime provided significant protection in experimental animal models of motor neuron disorders and more particularly ALS. Olesoxime is orally active, crosses the blood brain barrier, and is well tolerated. Collectively, its pharmacological properties designate olesoxime as a promising drug candidate for motor neuron diseases.
Keywords: TRO19622; olesoxime; neuroprotection; mitochondrial permeability transition pore; motor neuron disease; amyotrophic lateral sclerosis; spinal muscular atrophies TRO19622; olesoxime; neuroprotection; mitochondrial permeability transition pore; motor neuron disease; amyotrophic lateral sclerosis; spinal muscular atrophies
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Bordet, T.; Berna, P.; Abitbol, J.-L.; Pruss, R.M. Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound. Pharmaceuticals 2010, 3, 345-368.

AMA Style

Bordet T, Berna P, Abitbol J-L, Pruss RM. Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound. Pharmaceuticals. 2010; 3(2):345-368.

Chicago/Turabian Style

Bordet, Thierry; Berna, Patrick; Abitbol, Jean-Louis; Pruss, Rebecca M. 2010. "Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound." Pharmaceuticals 3, no. 2: 345-368.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert